Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters

Net Income Margin Trends of Top Pharma Companies

__timestampAstraZeneca PLC, AZNEli Lilly and Company, LLYGSK plc, GSKTakeda Pharmaceutical Company Limited, TAK
Saturday, October 1, 20220.0803961810.26537292170.19807483730.1086379019
Sunday, January 1, 20230.16573214450.19323275860.21435764640.0325616322
Saturday, April 1, 20230.15925017520.21212449320.22624686540.0844450028
Saturday, July 1, 20230.119561434-0.00604299580.1796980484-0.046045927
Sunday, October 1, 20230.07984031940.23410738340.04346746150.0951415875
Monday, January 1, 20240.17185897940.25580520070.1420616596-0.0028719089
Monday, April 1, 20240.14894110370.26250132710.1487823440.0788483348
Loading chart...

Infusing magic into the data realm

Net Income Margin Trends of Leading Pharmaceutical Giants

A Comparative Analysis Over the Last 8 Quarters

In the ever-evolving pharmaceutical industry, understanding the financial health of leading companies is crucial. This analysis delves into the net income margins of four pharmaceutical giants—GlaxoSmithKline (GSK), AstraZeneca, Takeda, and Eli Lilly—over the past eight quarters, providing a comprehensive view of their profitability trends.

Key Insights

  • Eli Lilly has consistently outperformed its peers, boasting an average net income margin of approximately 20.3%. Despite a dip to -0.6% in Q3 2023, it rebounded strongly to 26.3% by Q1 2024.
  • GSK maintained a stable performance with an average net income margin of 15.7%. The highest margin was 22.6% in Q2 2023, reflecting robust financial health.
  • AstraZeneca showed moderate fluctuations, averaging a 13.4% net income margin. The lowest was 8.0% in Q4 2022, while the highest reached 17.2% in Q1 2024.
  • Takeda faced challenges, with an average net income margin of just 5.2%. The company experienced negative margins in Q3 2023 and Q1 2024, indicating potential financial instability.

Conclusion

This comparative analysis highlights the varying financial trajectories of these pharmaceutical leaders. Eli Lilly's strong recovery and GSK's steady performance contrast with AstraZeneca's moderate fluctuations and Takeda's financial challenges. Investors and stakeholders can leverage these insights to make informed decisions in the dynamic pharmaceutical landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
15 Sept 2024